Astragaloside IV activates the JAK2/STAT3 and ERK1/2 signaling pathways, upregulates the expression of endothelial eNOS and the production of NO, and improves endothelial dysfunction (Figure 2). The gene discussed is MAPK3; the disease is endothelial dysfunction.